Departments of *Dermatology
†Immunology, Institute for Cell Biology, University of Tübingen
‡CureVac GmbH, Tübingen, Germany
Financial Disclosure: Hans-Georg Rammensee is associated with CureVac GmbH, a company involved with mRNA development. All other authors have declared there are no financial conflicts of interest in regard to this work.
Supported by “PRO INNO” and the Fritz-Bender-Stiftung. Benjamin Weide and Jean-Philippe Carralot were supported by AKF and “Fortüne” grants from the University of Tübingen.
Reprints: Steve Pascolo, Department of Immunology, University of Tuebingen, Auf der Morgenstelle 15, 72076 Tuebingen, Germany (e-mail: [email protected]).
Supplementary figures are available at http://www.immunotherapy-journal.com.
Received for publication May 17, 2007; accepted July 23, 2007
Benjamin Weide and Jean-Philippe Carralot contributed equally to this work.
Author's Contributions: Dr Benjamin Weide: design of study, recruitment and treatment of patients, finding of financial support. Dr Jean-Philippe Carralot: production, analysis, and qualification of injectable mRNA libraries. Immunomonitoring of B-cell and T-cell immune response. Dr Anne Reese: recruitment and treatment of patients. Dr Birgit Scheel: analysis of toxicity data and optimization of immunomonitoring methods. Dr Thomas Kurt Eigentler: recruitment and treatment of patients. Dr Ingmar Hoerr: design of study, strategic and financial support. Prof Hans-Georg Rammensee: Design of study. Prof Claus Garbe: Principal investigator. Design of study. Steve Pascolo: design of study, supervision of RNA library production, supervision of immunomonitoring, strategic and financial support.